{{Drugbox
| Watchedfields = changed
| verifiedrevid = 462249027
| IUPAC_name = 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
| image = Mesoridazine.svg

<!--Clinical data-->
| tradename =  Serentil
| Drugs.com = {{drugs.com|CONS|mesoridazine}}
| MedlinePlus = a682306
| pregnancy_US = C
| legal_status = Rx-only
| routes_of_administration = Oral, intravenous

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 4%
| metabolism = Hepatic/renal
| elimination_half-life = 24 to 48 hours
| excretion = Biliary and renal

<!--Identifiers-->
| IUPHAR_ligand = 7227
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 5588-33-0
| ATC_prefix = N05
| ATC_suffix = AC03
| ATC_supplemental =  
| PubChem = 4078
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00933
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3936
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5XE4NWM740
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02671
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6780
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1088

<!--Chemical data-->
| C=21 | H=26 | N=2 | O=1 | S=2
| molecular_weight = 386.576 g/mol
| smiles = O=S(c2cc1N(c3c(Sc1cc2)cccc3)CCC4N(C)CCCC4)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SLVMESMUVMCQIY-UHFFFAOYSA-N
| melting_point = 130
| solubility = insoluble
}}

'''Mesoridazine''' '''(Serentil)''' is a [[piperidine]] [[neuroleptic]] drug belonging to the class of drugs called [[phenothiazine]]s, used in the treatment of [[schizophrenia]]. It is a metabolite of [[thioridazine]]. The drug's name is derived from the '''me'''thyl'''s'''ulf'''o'''xy and pipe'''rid'''ine functional groups in its chemical structure.

It has central antiadrenergic, antidopaminergic, antiserotonergic and weak muscarinic anticholinergic effects.

Serious side effects include [[akathisia]], [[tardive dyskinesia]] and the potentially fatal [[neuroleptic malignant syndrome]].

Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.<ref>[http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682306.html]</ref>

It currently appears to be unavailable worldwide. 

== References ==
{{Reflist|2}}

{{Antipsychotics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Muscarinic antagonists]]
[[Category:Phenothiazines]]
[[Category:Piperidines]]
[[Category:Sulfoxides]]
[[Category:Typical antipsychotics]]

{{nervous-system-drug-stub}}